Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cyclophosphamide vs methylprednisolone

Response to treatment (20% improvement)* · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes response to treatment (20% improvement)* compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
RR 2.05 [1.13, 3.73]
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
RR 0.86 [0.47, 1.57]
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

Adverse events ‐ Death · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes adverse events ‐ Death compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
RR 0.23 [0.03, 1.96]
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

SLICC scores (damage index) Scale: from 0 to 48 (lower is better) · patients with neuropsychiatric involvement in systemic lupus erythematosus

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

Disease activity · patients with neuropsychiatric involvement in systemic lupus erythematosus

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

Prednisone sparing · patients with neuropsychiatric involvement in systemic lupus erythematosus

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Cyclophosphamide vs methylprednisolone

Seizures · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes seizures compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus 2013 · Cochrane Headline outcomes only
RR 2.57 [0.92, 7.14]
1 study · 11 participants
Very low